{"entity":{"id":"cr-001","kind":"drug","name":"CR-001","aka":["SKB118"],"tldr":"CR-001 is an experimental tetravalent bispecific antibody from Crescent Biopharma, in phase 2 trials for non-small cell lung cancer and advanced solid tumours.","summary":"CR-001 (SKB118) is a tetravalent bispecific antibody from Crescent Biopharma, with Sichuan Kelun-Biotech Biopharmaceutical as licensee (Greater China). A tetravalent bispecific antibody that blocks PD-1 and VEGF together; the company says it was designed to show the same cooperative pharmacology as ivonescimab, with PD-1 binding increased in the presence of VEGF. Its furthest stage is phase 2, for non-small cell lung cancer and advanced solid tumours. ClinicalTrials.gov registers it in 4 studies linked below. Global (ex-Greater China) phase 1/2 ASCEND trial recruiting; Kelun-Biotech runs phase 2 combination trials with sacituzumab tirumotecan in China under the name SKB118. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Crescent Biopharma: crescentbiopharma.com","url":"https://www.crescentbiopharma.com/pipeline"},{"label":"Crescent Biopharma: crescentbiopharma.com","url":"https://www.crescentbiopharma.com/pipeline"},{"label":"Crescent Biopharma: crescentbiopharma.com","url":"https://www.crescentbiopharma.com/pipeline"},{"label":"Crescent Biopharma: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07586943"},{"label":"ClinicalTrials.gov: trials of CR-001","url":"https://clinicaltrials.gov/search?intr=CR-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","metastatic-cancer"],"sections":[],"technologies":[],"targets":["pd1","vegf"],"drugs":[],"companies":["crescent-biopharma","kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07335497","nct07586943","nct07697586","nct07854509"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CR-001","modality":"Tetravalent bispecific antibody","mechanism":"A tetravalent bispecific antibody that blocks PD-1 and VEGF together; the company says it was designed to show the same cooperative pharmacology as ivonescimab, with PD-1 binding increased in the presence of VEGF.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cr-001/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"crescent-biopharma","kind":"company","name":"Crescent Biopharma","route":"/companies/crescent-biopharma/"},{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}],"trial":[{"id":"nct07854509","kind":"trial","name":"A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure","route":"/trials/nct07854509/"},{"id":"nct07335497","kind":"trial","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07335497/"},{"id":"nct07586943","kind":"trial","name":"SKB118 Injection in Advanced Solid Tumors","route":"/trials/nct07586943/"},{"id":"nct07697586","kind":"trial","name":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","route":"/trials/nct07697586/"}]}}